Keck School Faculty

Afsaneh Barzi, MD
Afsaneh Barzi, MD
Associate Professor Of Clinical Medicine
Medicine
NOR 3440 Health Sciences Campus Los Angeles
Barzi earned her M.D. from Tehran University of Medical Sciences, then went on to earn a Master’s in Health Informatics and a Doctorate in Public Health Management and Policy Sciences from the University of Texas Health Science Center in Houston. She recently completed a fellowship in hematology and oncology at the Cleveland Clinic’s Taussig Cancer Center.

Her research interests are the development of new cancer therapies as well as healthcare economics and metrics of healthcare quality for improving patient care. Dr. Barzi has proposed a phase II study to investigate the overall survival benefit of adding lapatinib to docetaxel in a second line setting in patients with trastuzumab-resistant, HER2-positive gastric cancer.

“Delivery of personalized treatment to gastric cancer patients has lagged behind other diseases,” Barzi says. “My goal is to establish a second-line treatment for these patients that are HER2-positive and to better understand the mechanisms of resistance to HER2-targeted therapy, paving the way for new therapies that can overcome that resistance.”

National Cancer Institute: Travel Award for Markers in Cancer, 2013

Southwest Oncology Group: Young Investigator Award, 2011

Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providersUrol Oncol. 2017 07; 35(7):459. e15-459. e24. . View in PubMed

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Cancer. 2019 Aug 09. . View in PubMed

Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims Arch Osteoporos. 2019 Jul 28; 14(1):83. . View in PubMed

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study Lancet Oncol. 2019 Jun 28. . View in PubMed

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients Int J Cancer. 2019 May 15; 144(10):2567-2577. . View in PubMed

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Cancer Control. 2019 Jan-Dec; 26(1):1073274819847642. . View in PubMed

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials Eur J Cancer. 2019 Jan; 107:115-123. . View in PubMed

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial Eur J Cancer. 2019 Jan; 107:100-114. . View in PubMed

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials Eur J Cancer. 2018 Dec 14; 107:115-123. . View in PubMed

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial Eur J Cancer. 2018 Dec 13; 107:100-114. . View in PubMed

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States Clin Colorectal Cancer. 2018 Dec; 17(4):e751-e761. . View in PubMed

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients Int J Cancer. 2018 Nov 09. . View in PubMed

Tertiary Care Multidisciplinary Teams Associated with Improved Survival in Rectal Cancer Patients: A Comparative Study Am Surg. 2018 Oct 01; 84(10):1645-1649. . View in PubMed

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer Pharmacogenomics J. 2018 Sep; 18(5):623-632. . View in PubMed

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States Clin Colorectal Cancer. 2018 Aug 24. . View in PubMed

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer Pharmacogenomics J. 2018 Jun 21. . View in PubMed

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types Biochem Biophys Res Commun. 2018 Jun 07; 500(3):621-625. . View in PubMed

Outlooks on Epstein-Barr virus associated gastric cancer Cancer Treat Rev. 2018 May; 66:15-22. . View in PubMed

Outlooks on Epstein-Barr virus associated gastric cancer Cancer Treat Rev. 2018 Mar 31; 66:15-22. . View in PubMed

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib Clin Colorectal Cancer. 2018 Feb 27. . View in PubMed

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States Clin Colorectal Cancer. 2018 12; 17(4):e751-e761. . View in PubMed

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer Pharmacogenomics J. 2018 09; 18(5):623-632. . View in PubMed

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib Clin Colorectal Cancer. 2018 06; 17(2):e395-e414. . View in PubMed

Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies Semin Oncol. 2018 06; 45(3):133-150. . View in PubMed

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials Pharmacogenomics J. 2018 01; 18(1):43-48. . View in PubMed

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. . View in PubMed

Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature Front Oncol. 2018; 8:259. . View in PubMed

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab Cost Eff Resour Alloc. 2018; 16:30. . View in PubMed

Trends in colorectal cancer mortality in hispanics: a SEER analysis Oncotarget. 2017 Dec 12; 8(65):108771-108777. . View in PubMed

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Cancer. 2017 Nov 15; 123(22):4506-4514. . View in PubMed

DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer Cancer. 2017 Oct 01; 123(19):3732-3743. . View in PubMed

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666. . View in PubMed

Colorectal cancer statistics, 2017 CA Cancer J Clin. 2017 May 06; 67(3):177-193. . View in PubMed

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer Eur J Cancer. 2017 11; 86:197-206. . View in PubMed

Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese Cancer Epidemiol Biomarkers Prev. 2017 04; 26(4):587-596. . View in PubMed

Colorectal cancer statistics, 2017 CA Cancer J Clin. 2017 05 06; 67(3):177-193. . View in PubMed

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer Ann Oncol. 2017 05 01; 28(5):1015-1022. . View in PubMed

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial Int J Cancer. 2017 07 15; 141(2):383-392. . View in PubMed

Comparative effectiveness of screening strategies for colorectal cancer Cancer. 2017 05 01; 123(9):1516-1527. . View in PubMed

Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population Clin Colorectal Cancer. 2016 Dec; 15(4):e221-e227. . View in PubMed

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012 Oncotarget. 2016 Aug 16; 7(33):53668-53678. . View in PubMed

Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. . View in PubMed

Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population Clin Colorectal Cancer. 2016 12; 15(4):e221-e227. . View in PubMed

Lost in Translation: The Patient-Physician Relationship in the Molecular Era J Palliat Med. 2015 Nov; 18(11):987-8. . View in PubMed

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach Mol Cancer Ther. 2015 Oct; 14(10):2401-8. . View in PubMed

We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer J Adolesc Young Adult Oncol. 2015 Sep; 4(3):105-7. . View in PubMed

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases Ann Oncol. 2015 Aug; 26(8):1728-33. . View in PubMed

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results Int J Clin Oncol. 2015 Jun; 20(3):518-24. . View in PubMed

Comparative effectiveness of screening strategies for Lynch syndrome J Natl Cancer Inst. 2015 Apr; 107(4). . View in PubMed

Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3):183-4; 186.. View in PubMed

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer Ann Oncol. 2015 Feb; 26(2):332-9. . View in PubMed

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. . View in PubMed

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. . View in PubMed

Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment Expert Opin Biol Ther. 2014 Sep; 14(9):1319-32. . View in PubMed

Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. . View in PubMed

Molecular pathways: Estrogen pathway in colorectal cancer Clin Cancer Res. 2013 Nov 01; 19(21):5842-8. . View in PubMed

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States Mol Cancer Ther. 2013 Oct; 12(10):2261-72. . View in PubMed

Angiogenesis-related agents in esophageal cancer Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. . View in PubMed

Screening for Lynch syndrome in the general population-letter Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. . View in PubMed

Myelodysplastic syndromes: a practical approach to diagnosis and treatment Cleve Clin J Med. 2010 Jan; 77(1):37-44. . View in PubMed

A Bayesian model for triage decision support Int J Med Inform. 2006 May; 75(5):403-11. . View in PubMed

Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS Stud Health Technol Inform. 2005; 116:223-8. . View in PubMed

Self-administered decision support tool for triage: results of a retrospective study Stud Health Technol Inform. 2002; 85:45-51. . View in PubMed

Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer Tumori. 1979 Jun 30; 65(3):339-44. . View in PubMed

Powered by SC CTSI
Go to Top